2025 Germany Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 Germany Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in Germany include Affimed, Heidelberg Pharma, Evotec, and iOmx Therapeutics. Affimed, based in Mannheim, focuses on clinical-stage immuno-oncology by developing innate cell engagers using its proprietary ROCK platform to activate immune cells against cancer. Heidelberg Pharma pioneers in Antibody Drug Conjugates (ADC) technology targeting cancer with the toxin Amanitin. Evotec, headquartered in Hamburg, is a major contract research organization (CRO) providing integrated drug discovery solutions and has extensive partnerships in oncology. iOmx Therapeutics, located in Martinsried, specializes specifically in cancer immunotherapy development, offering advanced biologics and platform services in the field.
These companies are central to Germany's growing role in cancer immunotherapy drug discovery, combining innovative biotechnologies and outsourcing services to accelerate therapeutic development. Germany’s market benefits from a strong biotech ecosystem, government support, and collaborations that bridge academic research and clinical development. Outsourcing drug discovery is increasingly favored due to cost efficiency and expert capabilities, making these companies key players in advancing cancer immunotherapies globally, particularly within Europe’s competitive oncology sector.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in Germany include Affimed, Heidelberg Pharma, Evotec, and iOmx Therapeutics. Affimed, based in Mannheim, focuses on clinical-stage immuno-oncology by developing innate cell engagers using its proprietary ROCK platform to activate immune cells against cancer. Heidelberg Pharma pioneers in Antibody Drug Conjugates (ADC) technology targeting cancer with the toxin Amanitin. Evotec, headquartered in Hamburg, is a major contract research organization (CRO) providing integrated drug discovery solutions and has extensive partnerships in oncology. iOmx Therapeutics, located in Martinsried, specializes specifically in cancer immunotherapy development, offering advanced biologics and platform services in the field.
These companies are central to Germany's growing role in cancer immunotherapy drug discovery, combining innovative biotechnologies and outsourcing services to accelerate therapeutic development. Germany’s market benefits from a strong biotech ecosystem, government support, and collaborations that bridge academic research and clinical development. Outsourcing drug discovery is increasingly favored due to cost efficiency and expert capabilities, making these companies key players in advancing cancer immunotherapies globally, particularly within Europe’s competitive oncology sector.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
